reason report
model updat increas rev/ep estim
bottom line conjunct outlook made
model updat see op op model also
roll forward valuat methodolog reflect multipl
base estim
pt goe pt vs prior appli current
yr forward multipl higher ep vs
pt goe vs appli
expand vs today forward multipl stock
continu see valuat gap/discount vs large-cap peer narrow
compani inform svb leerink llc research
pleas refer page import disclosur price chart analyst certif
outperform rate pt vs prior light neotract
acquisit see clearer pathway toward hsd org sale growth rang
vascular solut vsi close feb neotract
close deal organ mix strong record execut come
 integr includ under-promis over-deliv initi synergy/sal
target less near-term cost synergi potenti associ neotract
top-lin accret potenti excit us deal believ
potenti transform hsd revenu grower out-year also think
could addit sales/ep momentum out-year factor model
consid increas contribut neotract ou market bulk
exist urolog footprint current sit urolift today minim presenc
eventu revenue contribut ezplaz frozen plasma project possibl
commerci time-frame increas revenue contribut manta acquir
essenti medic acquisit pma approv potenti futur tuck-in
 addit restructur opportun addit program alreadi underway
project earn power ep compound-annual-growth-rate op margin
expans potenti given confid top-lin acceler
territori mid-teen ep growth profil -- -both upper-end
peersw think sustain current premium group assum
multipl ep suggest pt
trade ep slightli peer group hospit suppli
compani compani relev
alc trade ep
given confid top-lin acceler hsd territori margin expans driven
acceler mid-to-high teen profit growth profil -- -both upper-end
peersw think sustain premium group appli current
forward price-to-earnings multipl multipl ep suggest pt wed note
compani med-tech msd-hsd top line growth acceler and/or low-mid-
valuat could risk new product launch organiz improv effort
planned/prior integr synergi cost-cut effort prove challeng take longer
expect implement neotract acquisit integr time fashion
reason uptak compani urolift platform materi quickli
project could put pro forma sales/ep forecast risk well tough competit
larger hospit suppli compani could hinder abil make inroad new
product launch hospitalsin effort rein cost preserv profit given numer
global macroeconom challeng uncertainti relat political/healthcar reform tighten
belt grow less will negoti price hospit suppli product could make
harder drive higher product compani typic sold
discount market rate attempt bring market rate newli launch
achiev sustain price increas key driver long-term gross/oper margin
improv instrument order achiev long-term sales/profit goal
discret item neg impact organ cc revenue growth compani base busi
prove transient take longer resolv expect would like damag
management credibl decreas investor confid org revenue growth acceler thesi
key part invest thesi
rate zimmer hold nyse outperform pt view strong
turnaround stori make new leadership think compani improv
execut eventu drive faster ep growth compani come side
manufactur suppli recoveri post re-acceler top line given potenti
may even begin engag portfolio re-shap beyond
shift exposur toward faster-grow end-mkts/subseg end day
gener solid hold market-lead posit across key orthoped market
favor demograph tailwind trade signific price-to-earnings p/
 discount large-cap med-tech think zbh steep discount vs peer narrow
compani improv execut eventu drive faster ep growth
trade fairli steep discount large-cap med-tech group price-to-earnings average
believ level discount vs large-cap peer warrant given average top-lin
growth think current discount vs peer wide believ ultim
busi time capabl gener hsd ep growth gradual
top-lin acceler mid-singl digit growth territori pt assum trade
ep narrow valuat gap vs large-cap
med-tech average forward multipl would zbh current price-to-earnings
multipl would still repres discount large-cap exclud ew
group average price-to-earnings compani large-cap group includ alc
risk valuat includ abl execut post-biomet ldrh deal
synergi guidanc take longer address suppli issu build safeti
stock inventori -- -which could limit co abil meet demand and/or regain market share futur
qtr crucial sale growth acceler stori underli ortho recon growth
rate slow vs current expect level price eros industri ortho recon price
occur dramat pace expect wors steadi y/i declin
rang unabl off-set asp price declin posit mix benefit relat new
product offer could hinder long-term share price appreci
robot total knee categori begin acceler faster-than-expect and/or abl
capit rosa knee applic time fashion fda approv
dollar million except ep
svb leerink llc estim compani inform
restat report statement effect januari includ revenu geographi revenu product comparison prior
comment chang model
rev/ep estim basic
revenue increas modestli higher
intervent access manta
book intervent urolog urolift
estim partial off-set primarili lower
revenu project
increment us manta revenue think
urolift growth highli like
revenue increas modestli primarili
due higher manta revenue contribut
assumpt well aggress urolift
ep estim increas
primarili due higher revenue assumpt
ep estim unchang
dollar million except per share data
good sold
oper incom ex-item amort
pre-tax incom ex-item amort
dilut averag share million
sg adjust sale
sg adjust ex-amort sale
 total sale
oper expens adjust sale
oper expens adjust ex-amort sale
day adj sale organ growth rate ex- acq
compani report svb leerink llc estim
teleflex incorpor restat segment revenu
dollar million except per share data
sale mix
compani report svb leerink llc estim
restat report statement effect januari includ revenu geographi revenu product comparison prior estim
million except ep
compani report svb leerink llc estim
revenue estim increas
organ cc growth y/i unchang
ep estim unchang
revenue estim increas reflect
organ cc growth y/i vs prior
increas due higher rosa placement
assumpt vs prior think believ
conserv -- -we model
placement higher set revenue partial
off-set conserv spine growth us
ep estim decreas
go priorit sale growth nearer-term
driver higher revenue growth -- -a trade-off investor
enthusiast view margin
expans possibl
project flat y/i margin leav expans
upsid model emb y/i
margin expans vs prior think
revenue estim increas reflect
organ cc growth y/i vs prior
primarili due higher rosa placement
assumpt model higher set
growth higher dental growth partial off-set
conserv spine growth assumpt
ep estim increas
higher revenu despit also slightli higher
 sg expens assumpt model
y/i margin expans base
case think could well prove
conserv especi sale upsid
dollar million except per share data
product sold ex-intang amort
research develop expens
sell gener administr expens
income/ loss attribut non-controlling
adj dilut averag share million
gross margin ex devic tax
oper expens sale
sg sale
 sale
compani data svb leerink llc estim
note restat certain incom statement item reflect adopt account standard updat revenu contract custom topic account standard updat
dollar million
total sale adjust divestitur
y/i growth organ adjust cc day
y/i growth pro-forma adjust cc day
dollar million
compani report svb leerink llc estim
note restat certain incom statement item reflect adopt account standard updat revenu contract custom topic account standard updat
cement impact vs prior forecast
